Rivaroxaban and early periprostethic joint infection: our experience

Rivaroxaban and early periprostethic joint infection: our experience


  • Paolo Di Benedetto
  • Andrea Zangari
  • Dania De Franceschi
  • Enrico Daniele Di Benedetto
  • Vanni Cainero
  • Alessandro Beltrame
  • Renato Gisonni
  • Araldo Causero


acute early periprostethic joint infection, Rivaroxaban, Total Hip Arthroplasty


Background and aim of the work: Periprostethic joint infection (PJI) is a severe post-operative complication after Primary Total Hip Arthroplasty (THA). According to the classification of PJI early acute PJI occurs within 4 weeks from surgery. Some authors think that Rivaroxaban is a risk factor in the incidence of early acute PJI. We analyze our experience about this item. Materials and methods: We analyze our experience from 1st January 2015 to 31th December 2016. We consider all consecutive hip arthroplasty implants in this period. Results: In the 205 patients analysed we not find early acute PJI in Rivaroxaban group nor in the others assuming another kind of thromboprophylaxis. Conclusions: In our series there is no evidence of association between Rivaroxaban and early acute PJI. This is a retrospective cohort study, so we need more studies and more robust experimental designs to confirm these results. 







How to Cite

Rivaroxaban and early periprostethic joint infection: our experience. Acta Biomed [Internet]. 2017 Oct. 18 [cited 2024 Apr. 24];88(4 -S):38-42. Available from: https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/6792

Most read articles by the same author(s)

1 2 3 4 > >>